• Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New IMV Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMV

Analyst Price Target is $0.00
This price target is based on 1 analysts offering 12 month price targets for IMV in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for IMV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in IMV. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2023HC WainwrightDowngradeBuy ➝ NeutralLow
3/16/2023HC WainwrightLower TargetBuy$65.00 ➝ $19.00Low
2/13/2023HC WainwrightReiterated RatingBuy$65.00N/A
12/21/2022HC WainwrightBoost TargetBuy$13.00 ➝ $65.00Low
5/13/2022Echelon Wealth PartnersReiterated RatingBuyLow
3/18/2022Raymond JamesLower TargetMarket Perform$17.50 ➝ $15.00High
2/25/2022Raymond JamesSet TargetMarket Perform$17.50Medium
12/22/2021Raymond JamesSet TargetMarket Perform$17.50Low
11/12/2021Raymond JamesLower TargetMarket Perform$20.00 ➝ $17.50High
9/22/2021Cantor FitzgeraldInitiated CoverageOverweight$40.00Medium
8/11/2021National Bank FinancialReiterated RatingSector Perform Market WeightLow
7/23/2021Wells Fargo & CompanyInitiated CoverageOverweight$13.80High
7/16/2021Raymond JamesLower TargetMarket Perform$30.00 ➝ $20.00High
5/13/2021Raymond JamesSet TargetMarket Perform$30.00Low
3/18/2021Leede Jones GabReiterated RatingSpeculative BuyHigh
3/18/2021National BanksharesLower TargetSector Perform$70.00 ➝ $52.50Medium
3/18/2021Raymond JamesReiterated RatingMarket Perform$30.00Medium
12/29/2020Raymond JamesSet TargetMarket Perform$30.00N/A
12/4/2020Raymond JamesSet TargetMarket Perform$30.00Low
11/11/2020Raymond JamesSet TargetMarket Perform$30.00Medium
11/5/2020Raymond JamesSet TargetMarket Perform$30.00Medium
10/9/2020Raymond JamesSet TargetMarket Perform$30.00Medium
8/12/2020HC WainwrightReiterated RatingBuy$130.00High
8/7/2020National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market WeightMedium
8/6/2020Raymond JamesSet TargetMarket Perform$30.00Low
7/22/2020HC WainwrightReiterated RatingBuy$130.00Low
7/21/2020Industrial Alliance SecuritiesInitiated CoverageBuy$100.00Low
7/15/2020Raymond JamesSet TargetMarket Perform$30.00High
7/14/2020Wells Fargo & CompanyBoost Target$85.00 ➝ $110.00N/A
6/1/2020Raymond JamesSet TargetMarket Perform$30.00High
6/1/2020HC WainwrightReiterated RatingBuy$130.00High
5/25/2020Echelon Wealth PartnersReiterated RatingBuy$90.00Medium
5/19/2020Raymond JamesSet TargetMarket Perform$30.00High
5/18/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$25.00 ➝ $85.00High
5/15/2020HC WainwrightBoost TargetBuy$115.00 ➝ $130.00High
3/31/2020HC WainwrightReiterated RatingBuy$115.00High
3/31/2020B. RileyDowngradeBuy ➝ Neutral$70.00 ➝ $30.00High
3/31/2020Raymond JamesSet TargetMarket Perform$30.00High
3/18/2020HC WainwrightReiterated RatingBuy$115.00High
3/18/2020Raymond JamesDowngradeOutperform ➝ Market Perform$45.00 ➝ $30.00High
2/27/2020Echelon Wealth PartnersReiterated RatingBuy$90.00High
2/26/2020Raymond JamesLower TargetOutperform$100.00 ➝ $45.00Medium
2/25/2020HC WainwrightReiterated RatingBuy$115.00High
2/25/2020B. RileyReiterated RatingBuy$110.00High
2/25/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$35.00High
2/10/2020HC WainwrightReiterated RatingBuy$115.00Medium
2/6/2020B. RileyReiterated RatingBuy$110.00Medium
1/28/2020BTIG ResearchInitiated CoverageBuy$80.00High
1/21/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$30.00 ➝ $60.00High
12/10/2019B. RileyReiterated RatingBuy$110.00High
12/10/2019Raymond JamesSet TargetOutperform$100.00High
12/9/2019HC WainwrightReiterated RatingBuy$115.00Low
11/25/2019OppenheimerInitiated CoverageOutperformHigh
11/12/2019Echelon Wealth PartnersReiterated RatingBuy$122.50Medium
11/11/2019HC WainwrightReiterated RatingBuy$115.00High
11/7/2019Raymond JamesSet TargetOutperform$100.00Low
10/28/2019Wells Fargo & CompanyInitiated CoverageMarket PerformLow
10/1/2019Raymond JamesSet TargetOutperform$100.00Low
9/30/2019HC WainwrightSet TargetBuy$115.00High
8/12/2019Raymond JamesSet TargetOutperform$100.00Low
6/13/2019Raymond JamesSet TargetOutperform$100.00Medium
6/12/2019HC WainwrightReiterated RatingBuy$115.00Medium
6/4/2019Echelon Wealth PartnersReiterated RatingBuyMedium
6/3/2019Raymond JamesSet TargetOutperform$100.00Medium
6/3/2019HC WainwrightReiterated RatingBuy$115.00High
5/29/2019B. RileyInitiated CoverageBuy ➝ Buy$110.00 ➝ $110.00High
5/13/2019Raymond JamesSet TargetMarket Perform$100.00Medium
5/10/2019HC WainwrightSet TargetBuy$120.00High
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/23/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
10/23/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/22/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/21/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
IMV logo
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.66
Low: $0.49
High: $0.91

52 Week Range

Now: N/A

Volume

44,800 shs

Average Volume

233,607 shs

Market Capitalization

$9.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of IMV?

The following Wall Street sell-side analysts have issued research reports on IMV in the last twelve months: HC Wainwright.
View the latest analyst ratings for IMV.

What is the current price target for IMV?

0 Wall Street analysts have set twelve-month price targets for IMV in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IMV in the next year.
View the latest price targets for IMV.

What is the current consensus analyst rating for IMV?

IMV currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IMV, but not buy more shares or sell existing shares.
View the latest ratings for IMV.

What other companies compete with IMV?

How do I contact IMV's investor relations team?

IMV's physical mailing address is 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4. The company's listed phone number is (902) 492-1819 and its investor relations email address is [email protected]. The official website for IMV is imv-inc.com. Learn More about contacing IMV investor relations.